Monsenso (MONSO) H2 2025 earnings summary

Executive summary

• Revenue declined 20% year-over-year to DKK 8.9m, mainly due to project delays and reduced funding revenue.

• Market challenges in Denmark and project delays in Spain negatively impacted financial performance and cash flow.

• Despite setbacks, significant progress was made in strategic projects and platform development, positioning for future growth.

• The company expanded its digital health platform, supporting 13 psychiatric and neurologic disorders and operating in 16 countries.

Financial highlights

• Revenue: DKK 8.9m in 2025, down from DKK 11.1m in 2024.

• Gross margin decreased to 40% from 45% year-over-year.

• Net loss widened to DKK (7.2m) from DKK (6.0m) in 2024.

• Operating expenses reduced to DKK 12.0m from DKK 13.4m, mainly due to lower employee costs.

• Cash flow from operating activities improved to DKK (1.5m) from DKK (7.0m) in 2024.

Outlook and guidance

• 2026 revenue expected around DKK 11m with EBIT of DKK (4m), subject to significant uncertainties regarding order intake and project progress.